US biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Monday that it has completed the transfer of the Investigational New Drug application (IND) for its breast cancer vaccine from Cleveland Clinic.
Anixa is now the trial sponsor for future development of the vaccine.
The company said that, with enrolment completed and encouraging immune response and safety data observed in the Phase 1 trial, it intends to advance the vaccine into a Phase 2 clinical trial and has assumed full sponsorship of the IND. Anixa is planning to use multiple clinical sites, including Cleveland Clinic, for the Phase 2 and other clinical trials.
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
Amgen's UPLIZNA receives US FDA approval
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011